Clinical trialNCT01925417CompletedPhase 2Interventional

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

SponsorRebiotix Inc.Enrollment34Recurrent Clostridium Difficile Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Dimitri Drekonja, MD
Veteran Administration Medical Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Arizona
Phoenix, Arizona, United States
Denver Health and University of Colorado
Denver, Colorado, United States
Borland-Groover Clinic
Jacksonville, Florida, United States
Edward Hines Jr Va Hospital (veterans Only)
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Ochsner Clinic
New Orleans, Louisiana, United States
Chevy Chase Clinical Research
Chevy Chase, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Detroit Medical Center
Detroit, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Mayo Clinic - Minnesota
Rochester, Minnesota, United States
Washington University
St Louis, Missouri, United States
Sanford Research/usd
Fargo, North Dakota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

RBX2660

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2013
Primary completion: 31 Mar 2014
Completion: 31 Jul 2014
Last update posted: 13 Nov 2019
Registered enrollment: 34
Registry id: NCT01925417

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.